Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -13K | -12K | -173K |
| Operating Income | -5M | -9K | -6M | -7M | -10M |
| EBITDA | -5M | -9K | -6M | -7M | -9M |
| Net Income | -5M | -9K | -6M | -7M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.71
+0.00% today
1Y Change
+185.00%
Window
Jun 26, 2025 → Jun 23, 2026
Coverage: 248 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Helix BioPharma Corp. (HBPCF) is a Healthcare stock with a market cap of $150.00M and listed on OTC. The stock last traded around $1.71 and up 185.0% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +100.0%, free cash flow +23.6% with operating margin 0.0% and ROIC -26.2%. Stock Foundry combines HBPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HBPCF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HBPCF Max Drawdown
-1.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for HBPCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$8.0M
-22.5% YoY
Free Cash Flow
-$9.3M
-42.9% YoY
Revenue Growth
+0.0%
EPS Growth
+100.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -13K | -12K | -173K |
| Operating Income | -5M | -9K | -6M | -7M | -10M |
| EBITDA | -5M | -9K | -6M | -7M | -9M |
| Net Income | -5M | -9K | -6M | -7M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65K | 1M | 808K | 3M | 4M |
| Total Assets | 19M | 1M | 1M | 4M | 4M |
| Total Liabilities | 3M | 2M | 2M | 3M | 5M |
| Shareholder Equity | 16M | -90K | -844K | 319K | -1M |
| Total Debt | 333K | 0 | 0 | 2M | 4M |
| Net Debt | 269K | -1M | -808K | -784K | 47K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
-42.9% YoY
Capital Expenditures
0
Free Cash Flow
9M
-42.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.8%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.